These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 24188905)

  • 1. FDA reveals new initiatives to deal with drug shortages.
    McCarthy M
    BMJ; 2013 Nov; 347():f6646. PubMed ID: 24188905
    [No Abstract]   [Full Text] [Related]  

  • 2. The FDA and the pharmaceutical industry: is regulation contributing to drug shortage?
    Roman A
    Albany Law Rev; 2013-2014; 77(2):539-77. PubMed ID: 24851322
    [No Abstract]   [Full Text] [Related]  

  • 3. Proposed accelerated FDA approvals for special medical use.
    Somberg JC
    Am J Ther; 2012 Nov; 19(6):393-4. PubMed ID: 23154227
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA reform plan edges closer to realisation.
    Marx V
    Lancet; 2012 Jun; 379(9832):2135. PubMed ID: 22690392
    [No Abstract]   [Full Text] [Related]  

  • 5. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA not NIH can speed new drugs.
    Miller HI
    Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
    [No Abstract]   [Full Text] [Related]  

  • 7. 2015 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2016 Feb; 15(2):73-6. PubMed ID: 26837582
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmaceuticals and medical devices: FDA oversight.
    ; Berry MD
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845
    [No Abstract]   [Full Text] [Related]  

  • 9. Today's FDA.
    Slater EE
    N Engl J Med; 2005 Jan; 352(3):293-7. PubMed ID: 15659733
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA chief attacks Canada's drug price controls.
    Webster P
    Lancet; 2003 Nov; 362(9398):1816. PubMed ID: 14661624
    [No Abstract]   [Full Text] [Related]  

  • 11. Regulatory watch: FDA new drug approvals in Q2 2018.
    Urquhart L
    Nat Rev Drug Discov; 2018 Jul; 17(8):536-537. PubMed ID: 30057412
    [No Abstract]   [Full Text] [Related]  

  • 12. Turning a blind eye.
    Nat Med; 2008 Jan; 14(1):1. PubMed ID: 18180702
    [No Abstract]   [Full Text] [Related]  

  • 13. Biomarker qualification pilot process at the US Food and Drug Administration.
    Goodsaid F; Frueh F
    AAPS J; 2007 Mar; 9(1):E105-8. PubMed ID: 17408233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obama takes action on drugs shortages.
    Roehr B
    BMJ; 2011 Nov; 343():d7158. PubMed ID: 22051520
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic drug approval: a US perspective.
    Nagori BP; Mathur V; Garg S
    Curr Med Res Opin; 2011 Mar; 27(3):541-5. PubMed ID: 21219120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Will FDA relinquish the "gold standard" for new drug approval? Redefining "substantial evidence" in the FDA Modernization Act of 1997.
    Kulynych J
    Food Drug Law J; 1999; 54(1):127-49. PubMed ID: 11758555
    [No Abstract]   [Full Text] [Related]  

  • 18. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA under pressure to relax drug rules.
    Ledford H
    Nature; 2012 Dec; 492(7427):19. PubMed ID: 23222585
    [No Abstract]   [Full Text] [Related]  

  • 20. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.